Georgia Medicaid Mental Health Drugs Guide (2026)

Mental health medications are some of the most consequential prescriptions in the Georgia Medicaid population. They keep people with serious mental illness out of hospitals, help older adults manage depression and dementia-related symptoms, treat the anxiety that accompanies chronic illness, and support recovery from substance use disorders. They are also some of the most heavily managed drugs in Medicaid because of cost, clinical complexity, intersection with nursing facility care, and concerns about over- and under-prescribing in pediatric, geriatric, and dual-eligible populations. For a Georgia family trying to fill a prescription for an antidepressant, an atypical antipsychotic for a loved one with schizophrenia, a benzodiazepine for longstanding anxiety, a mood stabilizer for bipolar disorder, or an ADHD stimulant for a child, the rules of coverage matter a great deal, and the rules are not obvious.

This guide explains how Georgia Medicaid mental health drugs are covered. It walks through the structure of the Georgia Preferred Drug List maintained by the Georgia Department of Community Health, the role of the Drug Utilization Review Board and the Pharmacy and Therapeutics Committee, the prior authorization and step therapy mechanics that affect most prescriptions, the special considerations for atypical antipsychotics and dementia behavioral medications, the role of pharmacy benefits managers under contracts with the three Georgia Families managed care care management organizations, the nursing facility psychotropic oversight framework including chemical restraint prohibitions and gradual dose reduction expectations, the Medicare Part D coordination for dual eligibles, the Medicare Low-Income Subsidy expansion under the Inflation Reduction Act of 2022, and the appeal and advocacy options available when coverage is denied or delayed. Brevy publishes this guide because mental health medication access shapes the quality of life of millions of Georgia families, and the rules are too often invisible until a prescription rejects at the pharmacy counter.

By Brevy Care Team · Last verified May 12, 2026

How Georgia Medicaid mental health drug coverage works

Section 1927 of the Social Security Act, enacted as part of the Omnibus Budget Reconciliation Act of 1990, established the Medicaid Drug Rebate Program. Drug manufacturers must enter into a rebate agreement with CMS as a condition of having their drugs covered by Medicaid. Rebates are calculated under a federal formula that includes a basic manufacturer rebate plus an additional inflation-adjusted rebate when manufacturer prices rise faster than inflation. For the operative rebate percentages and current rebate-program parameters, consult the CMS Medicaid Drug Rebate Program page.

The rebate program creates a strong incentive for states to cover essentially all FDA-approved drugs. Federal financial participation is available for outpatient drug expenditures, so states have a financial interest in maintaining broad coverage to take advantage of federal matching.

States can manage their drug formularies through Preferred Drug Lists under Section 1927(d). A PDL distinguishes preferred drugs (typically generics or drugs with favorable supplemental rebate agreements) from non-preferred drugs that may require prior authorization. The PDL is not a closed formulary; non-preferred drugs are still covered, but with additional administrative steps.

Section 1927(d) of the Social Security Act and the federal Medicaid implementing regulations create access protections for outpatient drugs. States must respond to prior authorization requests promptly, and an emergency supply must be available when a prior authorization decision cannot be made in time. These protections are essential for mental health drug access because psychiatric medications often cannot be safely interrupted or delayed. Consult the current DCH pharmacy manual and CMS guidance for the operative response timeframes and emergency supply parameters.

Section 1927(d) also gives prescribers the right to override the PDL with documentation of medical necessity, subject to the prior authorization process. Additional federal protections apply to specific drug classes that have been the subject of CMS guidance over the years.

Every state must maintain a Drug Utilization Review Board that reviews drug utilization patterns, identifies inappropriate prescribing, and recommends prior authorization criteria and educational interventions. Georgia's DUR Board operates under federal Medicaid regulations and meets on a published schedule.

The Georgia Preferred Drug List for mental health drugs

Georgia's PDL is maintained by the DCH Pharmacy Services Division with input from the Pharmacy and Therapeutics Committee and approval by the DUR Board. The PDL is updated on a periodic cadence and published on the DCH website. Specific drug-to-tier assignments shift over time, so use the structure below as a general orientation and pull the current PDL for the operative classification of any specific drug.

For the current PDL, current tier assignments, and current prior authorization criteria, consult the Georgia DCH Pharmacy Services Division page directly.

How prior authorization and step therapy work in Georgia Medicaid

Prior authorization is the process by which the prescriber must obtain plan approval before a covered drug is dispensed. The PA request includes patient information, diagnosis, prior treatment history, and clinical justification for the requested drug. The state or its pharmacy benefits manager reviews the request against criteria set forth in the PDL and either approves, denies, or requests additional information.

Federal law requires a prompt decision on complete PA requests, and if the decision cannot be made in time, the pharmacy must provide an emergency supply while the PA process continues. In practice, most Georgia PA decisions for routine requests are made within the federal timeframe, with same-day decisions common for urgent requests. Consult the current DCH pharmacy manual for the operative response window and emergency-supply duration.

Step therapy is the requirement that the patient try one or more lower-tier drugs before a higher-tier drug is covered. For antidepressants, a common step therapy pattern is to try a generic SSRI at a therapeutic dose for an adequate duration; if the response is inadequate, try a second generic SSRI or an atypical antidepressant; if still inadequate, the prescriber can submit PA for branded SSRIs, SNRIs, or newer agents.

For atypical antipsychotics, step therapy has historically been limited because of access protections. Generic risperidone, olanzapine, quetiapine, and aripiprazole are typically preferred. Newer atypicals may require step therapy from one or more generic atypicals; PA approval is typically straightforward when the prescriber documents inadequate response or intolerable side effects with prior agents.

Step therapy in Georgia must comply with the federal prescriber-override authority. A prescriber can document medical contraindications, prior treatment failure with the required step therapy drug, or other clinical reasons for skipping the step. The CMO or PBM must accept appropriate documentation.

Mental Health Parity and Addiction Equity Act in Georgia Medicaid managed care

The Mental Health Parity and Addiction Equity Act of 2008 applies to Medicaid managed care through CMS implementing regulations. MHPAEA prohibits more restrictive treatment limitations on mental health and substance use disorder benefits than the predominant treatment limitations on medical and surgical benefits.

Treatment limitations include both quantitative limitations (such as quantity limits, day supply limits, visit limits, or dollar limits) and non-quantitative treatment limitations. Non-quantitative limitations include prior authorization, step therapy, medical necessity criteria, network adequacy, formulary design, and concurrent review.

For mental health drugs, MHPAEA analysis requires that any non-quantitative limitation applied to a mental health drug class be no more restrictive than the predominant non-quantitative limitation applied to medical and surgical drug classes. If a Georgia CMO requires step therapy for SSRIs but does not require similar step therapy for cardiovascular drugs, the parity analysis must justify the differential treatment.

MHPAEA does not prohibit all utilization management of mental health drugs; it requires that utilization management be applied in parity with medical and surgical management. Step therapy, prior authorization, and quantity limits remain available tools, but they must satisfy the parity analysis.

For families, MHPAEA provides a basis for challenging utilization management that appears more restrictive on mental health than medical drugs. Complaints can be filed with the U.S. Department of Labor (for employer-based plans), the HHS Office for Civil Rights, the Georgia Office of Commissioner of Insurance and Safety Fire (for state-regulated plans), or DCH (for Medicaid managed care plans).

Atypical antipsychotic access protections

Atypical antipsychotics (also called second-generation antipsychotics) have been the subject of extensive federal guidance because of clinical necessity in serious mental illness, the differential side-effect profiles that require individualized selection, and the risk of relapse and hospitalization when access is disrupted.

Federal Medicaid statute and CMS guidance have historically protected access. CMS State Medicaid Director Letters on PDL guidance have emphasized that PDLs and prior authorization should not interfere with clinically appropriate antipsychotic selection. The protection is not absolute; states can still apply step therapy and prior authorization, but the design must allow for clinical individualization.

Georgia's PDL has historically included common generic atypical antipsychotics as preferred without step therapy, with newer atypicals subject to step therapy or PA. Confirm the current tier and PA criteria for any specific drug on the DCH PDL.

Long-acting injectable antipsychotics (risperidone Consta, paliperidone Sustenna and Trinza, aripiprazole Maintena and Aristada, olanzapine Relprevv, fluphenazine decanoate, haloperidol decanoate) are typically covered through medical benefit (Medicare Part B for dual eligibles, Medicaid for non-dual) rather than the pharmacy benefit, with billing under HCPCS J-codes and administration in clinic settings.

Dementia behavioral medications and nursing facility considerations

Antipsychotics for dementia behavioral disturbances are a special and contested category. The FDA has issued black box warnings regarding increased mortality in elderly dementia patients receiving antipsychotics; CMS has issued multiple guidance documents emphasizing non-pharmacologic approaches as first-line for dementia behavioral management. For the operative warning text, consult current FDA prescribing information.

A national CMS dementia-care initiative set goals for reducing antipsychotic use in nursing facility residents with dementia. Quality measures track antipsychotic prevalence, and facilities with high prevalence receive surveyor attention.

Despite these efforts, antipsychotic use for dementia behavioral disturbances remains common when non-pharmacologic approaches are inadequate. The clinical decision rests with the prescriber and care team. Federal nursing-facility regulations require that any psychotropic drug use be supported by documented indication, appropriate dose, monitoring, and absence of adverse consequences, with gradual dose reduction attempts unless clinically contraindicated and documentation of the rationale for continued use.

Federal nursing-facility resident-rights regulations prohibit chemical restraints, defined as psychotropic drugs used for discipline or convenience rather than treatment of medical symptoms. The distinction between clinically indicated use and chemical restraint is clinical, but the documentation must establish the clinical basis.

For Georgia families with a loved one in a nursing facility receiving an antipsychotic for dementia behaviors, the questions to ask include: what specific behavioral targets are being treated, what non-pharmacologic interventions were attempted first, what is the planned duration, what monitoring is in place, has gradual dose reduction been attempted, and is informed consent documented for the black box warning. The Georgia Long-Term Care Ombudsman can assist with these questions.

Nursing facility psychotropic oversight

Federal nursing-facility pharmacy-services regulations require that a licensed pharmacist conduct monthly drug regimen review for every resident, identifying potential issues with drug selection, dosing, duration, monitoring, and interactions. The review is documented in the resident's record and shared with the prescriber and the interdisciplinary care team.

Federal regulations prohibit unnecessary drugs, defined as drugs used without indication, in excessive dose (including duplicate therapy), for excessive duration, without adequate indications for use, in the presence of adverse consequences, or in any combination of these factors.

Federal regulations specifically address psychotropic drugs, including antipsychotics, antidepressants, anti-anxiety drugs, and sedatives and hypnotics. Residents receiving psychotropic drugs must have:

• Documented indication for use, with specific target behaviors or symptoms identified
• Appropriate dose and duration
• Ongoing monitoring for therapeutic effect and adverse effects
• Gradual dose reduction attempted at appropriate intervals unless clinically contraindicated
• Documentation of the rationale for continued use if gradual dose reduction is not attempted or is not successful

These requirements apply to all nursing facility residents regardless of Medicaid status. For Medicaid beneficiaries, the requirements are enforced through both surveyor citations and through state Medicaid quality programs.

For Georgia families, monitoring psychotropic drug use in a nursing facility is an important advocacy function. Families have the right to participate in care planning, review the resident's medications, and request explanation of any psychotropic prescriptions. The Long-Term Care Ombudsman can assist when families have concerns.

Medicare Part D coverage for dual eligibles

For dual eligibles (Medicare and Medicaid), outpatient psychotropic drug coverage is generally through Medicare Part D, not Medicaid. The shift from Medicaid drug coverage to Part D coverage for dual eligibles took effect with Part D implementation under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

Part D plans cover most outpatient psychotropic drugs. The Part D protected class designation requires Part D plans to cover all or substantially all drugs in six protected classes: antipsychotics, antidepressants, anticonvulsants, antineoplastics, antiretrovirals, and immunosuppressants used for organ rejection. The protected class designation limits formulary exclusion and overly restrictive prior authorization, providing strong access protections for mental health drugs.

Benzodiazepines and barbiturates were initially excluded from Part D and later moved to Part D coverage by federal legislation. Dual eligibles now receive benzodiazepines (alprazolam, lorazepam, clonazepam, diazepam) and barbiturates (phenobarbital) through Part D plans. For the operative effective date and legislative authority, consult the current CMS Part D coverage guidance.

The Low Income Subsidy program subsidizes Part D premiums and reduces copays for low-income beneficiaries. The Inflation Reduction Act of 2022 expanded full LIS Extra Help to beneficiaries with incomes up to a federally set threshold. Full LIS recipients pay nothing for Part D premiums and pay nominal copays; for the current generic and brand copay amounts and the current income threshold, consult the SSA Extra Help page and the CMS LIS resource limits memo.

For dual eligibles in QMB or QMB+ status, Medicare Savings Programs interact with Part D cost-sharing in specific ways. Georgia generally does not pay Part D copays for QMB beneficiaries because Part D copays are nominal under LIS.

The three Georgia CMOs and their pharmacy benefits managers

Georgia operates its Medicaid managed care program through several care management organizations under the Georgia Families program for most non-dual eligibles. The current roster has included Amerigroup Georgia, CareSource Georgia, and Peach State Health Plan; confirm the current CMO list and PBM assignments on the DCH page.

Each CMO contracts with a pharmacy benefits manager. The PBM manages the pharmacy network, processes claims, administers prior authorization, and runs the formulary system. PBM assignments shift periodically with contract renewals.

CMO formularies must align with the DCH PDL for most drugs. CMOs can have plan-specific formulary additions, additional generic substitution policies, and plan-specific prior authorization criteria, but they cannot be more restrictive than the DCH PDL on covered drugs, and they must satisfy MHPAEA parity requirements.

When a beneficiary changes CMOs during the open enrollment window each year (or for plan-specific exceptions), prescription continuity is supposed to be maintained through transition fills. Transition fills allow the beneficiary to fill existing prescriptions for a defined window under the new CMO while the prescriber submits updated PA documentation.

When a CMO changes PBMs, similar transition mechanisms apply. Patients should not experience interruption of needed psychotropic medication, but disruption does occur in practice when transition processes fail.

Substance use disorder medications in Georgia Medicaid

Substance use disorder treatment medications are covered through the same PDL and pharmacy benefit structure as other prescription drugs, with several special considerations.

Buprenorphine (Suboxone, Subutex, Sublocade) is covered for opioid use disorder. Federal legislation enacted in the Consolidated Appropriations Act eliminated the prior DEA X-waiver requirement, allowing any DEA-registered prescriber with Schedule III authority to prescribe buprenorphine for opioid use disorder. Georgia Medicaid covers buprenorphine across the formulary with limited prior authorization in most cases.

Naltrexone (Vivitrol injectable, oral) is covered for both opioid use disorder and alcohol use disorder. The injectable form is administered monthly in clinic settings and is billed under medical benefit.

Acamprosate is covered for alcohol use disorder with relatively unrestricted access.

Disulfiram (Antabuse) is covered for alcohol use disorder, though clinical use has declined in favor of naltrexone and acamprosate.

Methadone for opioid use disorder is provided through opioid treatment programs rather than retail pharmacy. Georgia Medicaid covers methadone OTP services through a separate billing pathway, with daily directly-observed therapy and weekly take-home arrangements depending on stage of treatment.

The mainstreaming of addiction treatment combined with MHPAEA has substantially expanded access to medication-assisted treatment for substance use disorder in Georgia Medicaid.

Worked examples of Georgia Medicaid mental health drug coverage

Aisha, 67, Atlanta: depression and step therapy

Aisha is a 67-year-old recently widowed in Atlanta. Her primary care physician diagnoses major depressive disorder and prescribes escitalopram (Lexapro). At the pharmacy, the claim rejects: Georgia's PDL requires step therapy from a preferred generic SSRI before escitalopram. The pharmacist contacts Aisha's PCP, who agrees to switch to sertraline. Aisha starts sertraline. After several weeks her depression has improved modestly but not adequately. Her PCP submits a prior authorization request for escitalopram, documenting Aisha's inadequate response to sertraline at a therapeutic dose for an adequate duration. The PA is approved promptly. Aisha switches to escitalopram and achieves remission over the following weeks. The step therapy added a delay but ultimately did not block access to the medication her physician believed was most appropriate.

Marcus, 52, Albany: schizoaffective disorder in a nursing facility

Marcus has schizoaffective disorder. He was recently stabilized on olanzapine during an inpatient psychiatric admission for an acute episode. He has now transferred to a nursing facility in Albany for management of comorbid diabetes and a recent fall. Under the federal Preadmission Screening and Resident Review process, Marcus had a Level II evaluation that confirmed his serious mental illness and authorized Specialized Services. The nursing facility's licensed pharmacist conducts monthly drug regimen review. Olanzapine requires documentation of specific behavioral targets, planned duration, monitoring plan, and consideration of gradual dose reduction. Marcus's psychiatrist documents that he has had multiple prior decompensations on lower olanzapine doses and that gradual dose reduction has been attempted in past years with relapse each time, making further dose reduction clinically contraindicated. The continued-need documentation is filed. Marcus's Specialized Services include monthly psychiatric review by a Georgia Department of Behavioral Health and Developmental Disabilities-contracted psychiatrist, weekly individual therapy, and participation in the facility's behavioral health programming. His olanzapine is covered through Medicaid (Marcus is not dual-eligible) as a preferred generic with no PA.

Eleanor, 80, Macon: risperidone for dementia behaviors

Eleanor has advanced Alzheimer's disease with behavioral disturbances including agitation, occasional aggression, and wandering. Her nursing facility's medical director, after consultation with a geriatric psychiatry consultant and the interdisciplinary team, prescribes low-dose risperidone. Risperidone carries an FDA black box warning for increased mortality in elderly dementia patients. Per CMS guidance and federal nursing-facility regulations, the facility documents non-pharmacologic interventions previously attempted (consistent caregiving routine, music therapy, environmental modifications, redirection techniques), the specific behavioral targets (aggression toward other residents and staff during evening care), the planned duration with a reassessment date, the monitoring plan (regular behavioral tracking), informed consent from Eleanor's daughter as her healthcare proxy including discussion of the black box warning, and the rationale for selecting risperidone over alternatives. At reassessment, Eleanor's pharmacist documents that behaviors have improved substantially. The facility attempts gradual dose reduction. After a brief period, behaviors recur. The dose reduction is reversed and continued use is documented with clinical justification. Eleanor's daughter is updated and consents to continued use. The Long-Term Care Ombudsman reviews documentation at the family's request and finds it compliant with regulatory standards.

Diana, 75, rural Georgia: benzodiazepine in a dual eligible

Diana is a 75-year-old in rural Georgia with longstanding generalized anxiety disorder. She has taken alprazolam for many years, prescribed by her PCP. Diana qualifies for QMB (a dual eligible Medicare Savings Program category) and has been receiving Medicaid benefits coordinated with Medicare. Her benzodiazepine coverage runs through Medicare Part D rather than Medicaid. Her current Part D plan has alprazolam on the formulary with prior authorization required. Her PCP submits PA documenting longstanding use, prior unsuccessful attempts at gradual tapering, stable functioning on current dose, and absence of misuse markers (no early refills, no escalating doses, single prescriber, single pharmacy). PA is approved for an extended authorization period. Diana's geriatrician, in a separate visit, discusses the Beers Criteria concerns about benzodiazepine use in elderly patients (increased fall risk, cognitive impairment, risk of dependence). Diana acknowledges the concerns but declines to taper at this time. The geriatrician offers to revisit the discussion at future visits. Diana's care plan documents the shared decision-making.

Jamil, 34, Columbus: bipolar I disorder and PBM transition

Jamil has bipolar I disorder, stabilized on lithium and lamotrigine for several years. His Amerigroup Georgia plan covers lithium as a preferred generic with no PA. Lithium requires laboratory monitoring (serum lithium levels, renal function, thyroid function); Jamil's psychiatrist orders periodic labs. When Amerigroup transitions its PBM from one vendor to another, Jamil's existing prescriptions are honored under a transition fill at the same pharmacy. The PBM transition notice instructs his prescriber to submit updated PA documentation for the new PBM's system. The prescriber's office completes the documentation, and the new PBM updates Jamil's record with no gap in coverage. Jamil's pharmacist coordinates with the prescriber's office to ensure the transition is seamless. Jamil's clinical stability is maintained.

Tasha, 28, Atlanta: postpartum depression

Tasha delivers her baby and is enrolled in pregnancy and postpartum Medicaid coverage including the extended postpartum window that Georgia has adopted. She develops postpartum depression at several weeks postpartum, screened with the Edinburgh Postpartum Depression Scale by her obstetrician. The obstetrician refers her to a perinatal psychiatrist. The psychiatrist prescribes sertraline (a preferred generic SSRI, compatible with breastfeeding). No prior authorization is required. After several weeks, Tasha is improved but not fully remitted. The psychiatrist considers brexanolone IV infusion, which is FDA-approved for postpartum depression but requires extensive prior authorization, specialty pharmacy delivery, and an extended inpatient infusion. As an alternative, the psychiatrist considers zuranolone, an oral medication FDA-approved for postpartum depression that also requires extensive PA. After discussion of options, Tasha and her psychiatrist decide first to increase the sertraline dose and add brief psychotherapy through a community mental health program. Tasha achieves remission over the following weeks. Her sertraline and breastfeeding-compatible care are uninterrupted by formulary considerations.

Appealing a Georgia Medicaid mental health drugs denial

When a prior authorization is denied or a coverage decision is unfavorable, the beneficiary has appeal rights.

The first step is an internal appeal to the CMO (for managed care beneficiaries) or to DCH (for fee-for-service beneficiaries). The internal appeal must be requested within the timeframe specified in the denial notice. The CMO or DCH must respond within the regulatory timeframe, with expedited timeframes available when the beneficiary's health is at risk.

If the internal appeal is unsuccessful, the beneficiary can request a state fair hearing before Georgia's administrative hearings office. The fair hearing request must be filed within the timeframe specified in the denial. The fair hearing is conducted by an administrative law judge, with the beneficiary having the right to representation, presentation of evidence, and cross-examination of witnesses. Brevy's Georgia Medicaid appeals and fair hearings guide describes the process in detail.

For Part D denials affecting dual eligibles, the Medicare appeal process applies: Part D plan internal redetermination, Independent Review Entity reconsideration, ALJ hearing, Medicare Appeals Council review, and federal district court. GeorgiaCares SHIP counselors can assist with Part D appeals.

Medicare-Medicaid coordination appeals can involve both Medicare and Medicaid processes simultaneously. The Long-Term Care Ombudsman, GeorgiaCares SHIP, and Disability Rights Georgia can help navigate dual-track appeals.

Key contacts for Georgia Medicaid mental health drug coverage

Find personalized help navigating Georgia Medicaid mental health drug coverage at brevy.com.